pipeline
A two pillar r&d Strategy
Scinai’s R&D strategy is built on two complementary pillars: a VHH-based antibody platform applied across local and systemic formats, and PC111, a first-in-class monoclonal antibody program for severe orphan dermatologic diseases. Together, these pillars support disciplined risk management and multiple paths to value creation.
VHH-Based Antibody Platform: Flexible Formats, Disciplined Validation
Scinai’s VHH-based antibody platform enables the design of compact, high-affinity binding domains that can be deployed across multiple therapeutic formats, including local delivery and systemic antibody constructs.
The platform supports selective development of mono-,
bi-, and tri-specific antibodies across immune-mediated and inflammatory diseases, with a focus on capital-efficient validation through lead programs.
The VHH programs are based on licensed technology from the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen (Germany).
PC111: A First-in-Class Monoclonal Antibody for Severe Dermatologic Diseases
Complementing the VHH-based platform, Scinai is advancing PC111, a fully human, first-in-class monoclonal antibody targeting soluble Fas Ligand (sFasL).
PC111 is designed to treat severe, high-unmet-need dermatologic conditions, including Pemphigus and Stevens–Johnson syndrome / toxic epidermal necrolysis (SJS/TEN).
PC111 is licensed from Pincell S.r.l. (Italy), and is being developed as Scinai’s flagship near-term value driver.
Multiple Blockbuster Opportunities
With positive proof-of-concept data across its lead programs, proven regulatory pathways, and strong external validation for both NanoAb and mAb products, Scinai’s dual approach creates multiple blockbuster-scale opportunities while preserving strategic and financing optionality.
PIPELINE
Focused & Derisked Strategy
Portfolio Role
Flagship Value Driver
Primary Platform Validator
Selective Innovation Track
Future Platform Expansion
Asset
Target
Soluble FasL
IL-17A/F + Undisclosed
IL-17A/F
IL-4 / IL-4Rα, IL-13, TSLP
Target Indications
Pemphigus, SJS/TEN
Moderate–Severe Psoriasis, PsA, HS
Mild–Moderate Psoriasis
TH2 Diseases: AD, Asthma, COPD
Development Status
In vivo proof-of-concept completed
Lead clones generated
First pre-clinical PoC completed
Lead clones generated
Next major milestone
Toxicology panel studies and IND submission
In vivo PoC
Second pre-clinical PoC with Sustained release formulation
In vivo PoC
FIH clinical trial
PC111 mAb
Systemic
bi-specific NanoAb
Local
intradermal NanoAb
Systemic
multi-specific - NanoAb
YE 2027
YE 2027
TBD
TBD
Contact us
Get in touch to explore partnership opportunities and consult our CDMO specialists